Latest news with #Tylenol
Daily Mail
18 hours ago
- Health
- Daily Mail
Most common pain reliever taken by 100million Americans may make you more likely to cheat and do drugs
The world's most popular pain reliever may cause people to take more risks and reduce fear around risky decisions, leading to bolder behavior. Nearly a quarter of Americans take acetaminophen - the active ingredient in Tylenol - weekly and data estimates 100million Americans take it annually. Recently, scientists have been investigating how it might influence people's behavior on a larger scale. To measure the effects of acetaminophen, researchers from Ohio State University had over 500 college students participate in a risk-taking game. Some participants received a normal dose of acetaminophen, 1,000 mg, mirroring standard over-the-counter use, while others received a placebo. In the game, they inflated a virtual balloon to earn cash rewards. If it burst, they lost everything. The acetaminophen group pumped more aggressively and popped more balloons, suggesting they cared less about the risk of losing. In follow-up surveys, those on acetaminophen rated activities like bungee jumping or gambling as less risky than the placebo group, but only when the scenarios were emotionally charged. Researchers warned that while the changes in risk-taking are subtle, they're worth watching, mainly because acetaminophen is found in over 600 medications. The study suggested that acetaminophen's effect on risk-taking behavior likely goes beyond just dulling fear. The over-the-counter drug may also alter deeper cognitive and neurological processes, including by turning off the brain's alarm signals for danger. It may also reduce awareness of one's mistakes, and quiet a part of the brain that gives someone a gut feeling that danger is close. Dr Baldwin Way, co-author of the 2020 study and associate professor of psychology at Ohio State University, said: 'Acetaminophen seems to make people feel less negative emotion when they consider risky activities – they just don't feel as scared.' Dr Way conducted three experiments in his report, published in the journal Social Cognitive and Affective Neuroscience. Across these studies, 545 undergraduate students took part in a task developed in 2002 that is often used by researchers to measure risk-taking behavior: inflating a balloon in exchange for cash rewards. They can stop at any time, bank the money, and move on to the next balloon. The people who took acetaminophen pumped more and more, despite the risk of the balloon popping and losing all their money. In the balloon-popping game, people who took acetaminophen pumped 32 times compared to 29 times in the placebo group, and had more bursts, with 8.5 in the acetaminophen group compared to 7.9 in the placebo group. Dr Way said: 'If you're risk-averse, you may pump a few times and then decide to cash out because you don't want the balloon to burst and lose your money. 'But for those who are on acetaminophen, as the balloon gets bigger, we believe they have less anxiety and less negative emotion about how big the balloon is getting and the possibility of it bursting.' Previous research by Dr Way on the effects of acetaminophen on people's behavior has suggested that it dulls positive and negative emotions, including hurt feelings, distress over another person's suffering, and their joy. He posited in his latest research that the medicine reduces anticipatory anxiety. Typically, as the balloon expands, people feel growing anxiety about it bursting, making them stop pumping earlier. The drug may blunt this nervous feeling, though, causing people to take more risks. And according to Dr Way, 'increased risk-taking could have important effects on society.' With a dampened feeling of fear, anxiety and negative emotions, people may be more likely to partake in risky behavior, including cheating on partners, drinking excessively and taking drugs.
Yahoo
20 hours ago
- Business
- Yahoo
Factbox-Recent leadership changes at global consumer goods companies
(Reuters) -Procter & Gamble said on Monday CEO Jon Moeller is stepping away from the top job after four years in the role, and that he would be succeeded by Chief Operating Officer Shailesh Jejurikar. The reshuffle in the top position comes amid a string of similar announcements from consumer-facing companies globally. In the United States, companies are removing their CEOs at the fastest pace in two decades, with data showing that at least 41 CEOs have exited S&P 500 companies so far this year, compared with 49 for all of 2024. Here are some examples of major CEO changes in the past year: Company Details Nestle Nestle in August 2024 ousted CEO Mark Schneider and appointed company veteran Laurent Freixe to the role. Unilever The company ousted chief executive Hein Schumacher in February, replacing him with finance chief Fernando Fernandez. Kohls Kohl's fired CEO Ashley Buchanan in May after an investigation found he had pushed for deals with a vendor with whom he had a personal relationship, after little more than 100 days in the position. Stanley Black & Decker The power tools maker, in June, appointed operations chief Christopher Nelson as its next CEO and President, effective October 1, succeeding Donald Allan Jr., who is set to retire. Hershey Hershey, in July, named burger chain Wendy's chief Kirk Tanner as its CEO, effective August 18, replacing Michele Buck, who is set to retire. Hindustan Unilever Hindustan Unilever, in July, named Priya Nair as managing director and CEO, replacing Rohit Jawa well before the completion of his five-year term as the company's chief. Kenvue The Band-Aid and Tylenol maker fired its CEO Thibaut Mongon in July, laying what some investors expect will be the groundwork for an eventual sale of the entire company or pieces of it, and named director Kirk Perry as interim CEO. Diageo The Johnnie Walker whisky and Guinness beer maker's CEO, Debra Crew, stepped down after two years in the job in July, with finance chief Nik Jhangiani taking over in the interim. Procter & Gamble Procter & Gamble CEO said in July that CEO Jon Moeller is stepping away from the role; to be succeeded by Chief Operating Officer Shailesh Jejurikar. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
4 days ago
- Business
- Business Insider
How Johnson & Johnson Stock (JNJ) Discovered a New Lease of Life
Biopharma giant Johnson & Johnson's (JNJ) stock hit new highs this year after reporting its Q2 results on July 16th, giving the market a clear signal that it's reigniting growth with practically flawless numbers—a potential turning point for the second half of the year. The upwardly revised guidance and expectations for strong margin expansion, despite lingering litigation concerns, have brought fresh optimism to the stock and appeased shareholders clamoring for added value. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. While the stock isn't as discounted as it was earlier this year, valuations still look reasonable. Given JNJ's strong compounding potential and this renewed bullish momentum, I see it as a Buy. How J&J's Strong Quarter Sets the Stage for Growth Johnson & Johnson stock has been rangebound for years, weighed down by a mix of factors, including a massive wave of lawsuits claiming its talc-based baby powder caused cancer due to asbestos contamination, as well as expiring drug patents, such as its blockbuster Stelara losing exclusivity. Last but not least is sluggish growth and an eroded safe-haven reputation, since legacy consumer brands like Tylenol, Listerine, and Band-Aid have low growth and face margin pressure from cheap competition. According to TipRanks data, JNJ has underperformed the S&P quite considerably since 2024. Johnson & Johnson's latest Q2 earnings may mark a true inflection point toward more consistent alpha generation. The company delivered exactly what it needed— beating both earnings and revenue expectations —while issuing a notable upward revision to guidance: an additional $2 billion in forecasted sales and $0.25 more in projected EPS. For a pharma giant like J&J, that's a clear signal of renewed momentum following a prolonged period of litigation-related overhang. Management also reaffirmed its full-year outlook for a 300-basis-point improvement in operating margin, raising it from approximately 25.4% to 28.4%. Notably, the quarter wasn't just about numbers. J&J reported compelling 5-year trial results for its multiple myeloma immunotherapy—an encouraging sign in the fight against a challenging cancer. The company also set an ambitious goal: to become the global leader in oncology by 2030, with a target of over $50 billion in cancer drug sales. With a potential $5 billion peak opportunity in bladder cancer and a strong pipeline aimed at offsetting losses from aging blockbusters, J&J is signaling that real innovation is back at the forefront. Breaking Free from the Margin Squeeze While markets often reward margin expansion, Johnson & Johnson looks especially well-positioned to benefit going forward. In addition to raising full-year earnings guidance, the company also delivered positive updates on cost pressures— halving its expected tariff impact from $400 million to $200 million and projecting a $1.1 billion tailwind from favorable currency shifts as the U.S. dollar weakens. The reduced tariff burden is primarily attributed to the MedTech division, which is more exposed to global supply chains and international manufacturing than the pharmaceutical segment. That's a clear tailwind for margins and future profitability. It's also important to note how strategic portfolio decisions have helped set the stage for this improvement. The 2023 spin-off of Kenvue—essentially the entire Consumer Health business—removed a lower-margin segment from the mix, sharpening J&J's focus on higher-margin areas. This move highlights the company's commitment not only to defending margins but also to actively growing them. In today's market, stability alone isn't enough—investors are looking for real margin expansion, and Johnson & Johnson seems intent on delivering. Analysts have responded by raising their EPS estimates for 2025 and 2026 by about 2% compared to before Q2 earnings. They now expect full-year EPS in 2025 to hit $10.86 —an 8.7% increase from last year—and to reach $11.34 in 2026, representing an annual growth rate of 4.4%. Reasonable Valuation with Growth on the Horizon Johnson & Johnson is a vast, stable, and diversified company, so its valuation tends to reflect relative stability rather than wild growth. Looking at its forward earnings multiple, currently around 15.5x, it's basically in line with the five-year average. This is well above the lows seen earlier this year, when it traded as low as 11x forward earnings in January. To me, this suggests the valuation isn't necessarily cheap, but it's reasonable. Comparing J&J's current earnings multiples over the last twelve months to its main peers, the 17.5x P/E ratio sits close to the sector average. Except for Merck & Co. (MRK), J&J is actually one of the more discounted names in the group. Finally, with a dividend yield of almost 3%, the stock no longer appears exuberant, and the yield isn't particularly compelling—especially when compared to the 10-year U.S. Treasury yield. However, J&J's payout ratio is typically safe, at around 50% of earnings, which helps build shareholder trust. Additionally, the market is now anticipating a more positive growth trajectory following the recent upward revisions to guidance, both last quarter and earlier this year. Is JNJ Stock a Buy, Hold, or Sell? Wall Street sentiment on Johnson & Johnson remains mixed, with more caution than conviction among analysts. Of the 19 analysts who have issued ratings over the past three months, nine are bullish, while the remaining ten are neutral. The average price target stands at $176.35, suggesting a modest upside of approximately 4.3% from the current share price. Johnson & Johnson Positioned for Consistent Alpha Generation Johnson & Johnson has, in my view, successfully restored market confidence in both its innovation pipeline and cost discipline—key pillars that could drive renewed growth and support reliable shareholder returns for decades to come. For long-term investors, initiating a position now is essentially a bet on a proven dividend combined with steady capital appreciation—an attractive formula that has historically outperformed the broader market. While the stock appears fairly valued at current levels, it offers compelling potential for compounding returns and consistent alpha generation in the years ahead.
Buzz Feed
5 days ago
- Health
- Buzz Feed
13 Doctors Share Bad Health Habits You Should Stop
We recently wrote an article where doctors, nurses, and other medical workers revealed the "bad" habits people don't realize that can seriously harm their health. In the comments, even more health professionals shared things people downplay allll the time that are actually detrimental. Here's what they had to say: "Poor contact lens hygiene, including wearing your contacts to sleep or past their change date. I've seen so many eye infections lead to permanent scarring and vision loss. Also, never share contact lenses." "Not wearing earplugs to concerts. You should do it ALL THE TIME." "Excess caffeine, like five cups a day. Coffees are overly treated with pesticides. Excess coffee disturbs sleep. If you're older, switch to decaf and just one cup a day." "Please wear a helmet!!! When riding a bike, scooter, skateboard, or ATV. It's important to protect your brain!" "Dentist here. STOP SMOKING. Smoking leads to bad oral health and mouth cancers. Bad oral health can lead to blood infections, endocarditis, cardiovascular disease, pneumonia, pregnancy complications, etc. Just stop smoking. And yes, that includes the green stuff." "Alcohol will always be bad for you, even in moderation. The studies that claimed benefits from moderate drinking did not adjust for those with comorbid issues that already existed (those who didn't drink who smoked and then developed a stroke or heart disease weren't considered or 'adjusted' for to have a more plausible and valid study)." "Drinking even moderate amounts of alcohol while regularly taking Tylenol or products with Tylenol in them is extremely dangerous to your liver. I've known two people who almost died because of this; they had no idea how dangerous it was." "Obesity and lack of exercise — even think about joints, knees, and hips. Think of fractures. Sleep apnea. High blood pressure. Think about how it feels for your heart to work hard to pull all that extra weight around your middle. And no, it's not the same for muscular people, who don't lug around 200 extra pounds around their waist everywhere they go. Without exercise ... your body gets grossly de-conditioned." "Orthopaedic surgeon here. Ignoring T2DM (Type 2 Diabetes Mellitus) or smoking. Poorly controlled diabetes is one hell of a way to go. I've lopped off more feet/legs than I can count secondary to diabetic foot wounds gone awry. Smoking negatively impacts tissues and healing. Obesity up there, too. Every surgical and medication condition is made worse by obesity." "Carcinogenic activities, like sunbathing." "I work in healthcare. [Inactivity is harmful.] If you can, walk more. The walk to and from your car, around the house, or around Publix is not enough. Every now and then, you need to get up and actually walk. You have 15 minutes to scroll TikTok — you have 15 minutes to walk." "Occupational inhalation hazards — such as those encountered in mining, shipbreaking (asbestos exposure), and construction — can lead to serious health conditions including mesothelioma and pneumoconiosis." And finally... "Not wearing your seatbelt properly. Make sure it's over your pelvic bone. Too many people show up after an accident with internal injuries due to improper placement." Fellow doctors, nurses, and other medical professionals, what are some other "bad" habits that people may not realize are incredibly harmful to their health? Tell us in the comments, or if you prefer to remain anonymous, you can use the form below.
Business Wire
5 days ago
- Business
- Business Wire
Kenvue to Announce Second Quarter 2025 Results on August 7, 2025
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) will announce its second quarter 2025 financial results before the market opens on August 7, 2025. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results. The conference call can be accessed by dialing 877-407-8835 from the U.S. or +1 201-689-8779 from international locations. A live webcast of the conference call can also be accessed at with a replay made available after the live event. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the extraordinary power of everyday care. Our teams work every day to put that power in consumers' hands and earn a place in their hearts and homes. Learn more at
